NMOSD (Neuromyelitis Optica Spectrum Disorder)

Overview

Neuromyelitis optica spectrum disorder (NMOSD) is a rare inflammatory condition of the central nervous system. It mainly affects the optic nerves and spinal cord, and sometimes the brainstem. Most people with NMOSD test positive for aquaporin-4 (AQP4) antibodies; others have MOG antibodies or neither. Telling NMOSD apart from multiple sclerosis matters, because some MS medicines can make NMOSD worse.

Common Signs and Symptoms

• Sudden vision loss, often with eye pain
• Weakness, numbness or tightness in the limbs or trunk
• Bladder or bowel changes
• Hiccups, nausea or vomiting that won't stop
• Severe muscle spasms

When to Contact a Provider

New vision loss or new weakness needs urgent medical attention. If you have NMOSD, tell your neurologist about any new symptoms right away.

How Treatment May Help

Attacks are usually treated with high-dose steroids and sometimes plasma exchange. To help prevent attacks in adults with AQP4 antibody-positive NMOSD, a neurologist may prescribe a targeted therapy. Soliris blocks a protein in the complement system and may help lower the risk of relapses.

Therapies That May Be Available at Infuse Care

• Soliris (eculizumab): IV infusion; once a week for the first several weeks, then every two weeks; for adults with AQP4 antibody-positive NMOSD

Safety and Monitoring

Soliris carries a boxed warning for serious meningococcal infections. Meningococcal vaccines are required, ideally at least two weeks before the first dose, and it is available only through a safety program. Carry your patient safety card, and seek care right away for fever, headache with a stiff neck, or a rash.

Infusion reactions can occur, so you are monitored during treatment.

Your prescribing provider decides which treatment is right for you. Infuse Care administers prescribed therapies after a referral, a clinical review and any required insurance authorization, and we keep your provider's office updated on your care.